高尔基体糖蛋白73、磷脂酰肌醇蛋白聚糖3、甲胎蛋白异质体百分比联合检测在原发性肝癌诊断中的应用

目的 探讨高尔基体糖蛋白73(GP-73)、磷脂酰肌醇蛋白聚糖3(GPC3)、甲胎蛋白异质体百分比(AFP-L3%)联合检测在原发性肝癌诊断中的应用。方法 选择肝癌患者154例(肝癌组),肝硬化患者78例(肝硬化组),健康对照者56例(对照组),用酶联免疫法分别测出GP-73、GPC3、AFP-L3的浓度。然后分别按照检测项目统计分析。结果 肝癌组中GP-73、GPC3、AFP-L3%的水平明显高于肝硬化组和对照组(P<0.05);肝癌组中GP-73、GPC3、AFP-L3%的阳性率分别为66.2%、72.1%、53.2%。三项联合检测的阳性率可达到97.9%。高于任何单项和联合检测的敏感度和准确度。肝癌组中GP-73、AFP-L3%在AFP不同水平内比较,差异有统计学意义(P<0.05)。结论 GP-73、GPC3、AFP-L3%三者联合检测提高原发性肝癌诊断的敏感度和准确度,对鉴别诊断早期肝癌有参考意义。     

GP73和AFP联合检测在原发性肝癌中的诊断价值

目的探讨高尔基体蛋白73(GP73)和甲胎蛋白(AFP)联合检测在原发性肝癌(PHC)诊断中的价值。方法 AFP采用微粒子化学发光法,用美国雅培ARCHITECT i2000SR全自动化学发光仪进行定量检测;GP73采用ELISA法作定量检测,分别对PHC组105例,普通肝病组47例,其他肿瘤对照组43例和健康对照组50例进行两项指标的定量检测和分析。结果 PHC组血清GP73水平均明显高于普通肝病组、其他肿瘤组和健康对照组,差异有统计学意义(P0.05);GP73、AFP及二者联合检测对诊断PHC的灵敏度分别为79.05%、62.86%、94.29%,其受试者工作特征曲线(ROC曲线)下面积(AUC)分别为:0.84、0.71、0.95。结论 GP73和AFP联合检测能提高PHC诊断的敏感性和诊断价值。     

AFP、AFP-L3、GP73联合检测在肝癌诊断中的应用

目的 检测不同患者样本中甲胎蛋白（AFP）、甲胎蛋白异质体（AFP-L3）以及高尔基体蛋白73（GP73）的含量,研究AFP、AFP-L3、GP73在肝癌诊断中的应用.方法 收集肝癌患者样本、肝炎肝硬化样本以及正常健康人员样本,用电化学发光法检测AFP、AFP-L3及用ELISA法检测GP73含量.结果 1.本研究显示：AFP-L3%〉10%对肝癌诊断敏感度为89.1%;诊断特异度为94.4%[1];2.在101例肝癌标本中,GP73的阳性率为72.28%,AFP的阳性率37.62%,经过卡方检验,两者具有显著性差异（χ2=18.86,p〈0.01）;3.在所有非肝癌患者中,GP73的诊断特异性为93.44%;AFP的诊断特异性为86.48%.结论 AFP-L3、GP73 用于诊断肝癌效果明显优于AFP,可以显著提高对肝癌诊断的灵敏度和特异性,而且AFP-L3、GP73 相比AFP更不容易受到肝部炎症和其他部位肿瘤的影响.结合本人早期研究结果,将GP73、AFP-L3、AFP联合起来检测,能更好更快的对肝癌做出早期诊断.     

GP73和AFP检测在肝细胞肝癌诊断中的作用

目的通过检测肝细胞肝癌、慢性肝炎、肝硬化患者及健康体检者血清中甲胎蛋白(AFP)和高尔基体蛋白73(GP73)水平,对比分析AFP和GP73的阳性检出率,探讨GP73和AFP用于诊断肝细胞肝癌的临床意义。方法收集肝细胞肝癌、慢性肝炎、肝硬化患者及健康体检者血清样本,分别采用酶联免疫吸附法和化学发光法检测AFP和GP73水平。结果在肝细胞肝癌患者血清中,GP73阳性检出率为96.00%,AFP阳性检出率为84.00%,在肝细胞肝癌患者血清中,GP73水平为(702.64±54.35)ng/mL,AFP水平为(6 772.4±1 942.3)ng/mL,均明显高于肝硬化组、肝炎组及健康对照组,差异有统计学意义(P0.01);但是GP73和AFP联合检测在灵敏度和特异度方面与单独检测比较差异无统计学意义(P0.05)。结论 GP73和AFP在肝细胞肝癌患者中的阳性检出率和水平显著高于慢性肝炎组和肝硬化组,对于肝细胞肝癌患者早期诊断有一定参考价值。     

血清GP73及AFP-L3检测在原发性肝癌诊断中的意义

目的探讨高尔基体蛋白73(GP73)及甲胎蛋白异质体(AFP-L3)在原发性肝癌(PHC)诊断中的应用价值。方法分别采用酶联免疫吸附试验和亲和吸附法法检测68例PHC患者、42例肝硬化患者以及40例健康体检者血清GP73以及AFP-L3的含量,计算AFP-L3占总AFP的比率。结果检测血清GP73诊断PHC的临界值为123.8μg/L,曲线下面积为0.909,95%可信区间为0.835～0.957,诊断灵敏度为72.1%,特异度为91.4%;血清AFP-L3诊断PHC临界值为10.53%,曲线下面积0.885,95%可信区间为0.826～0.940,诊断灵敏度为70.6%,特异度为93.9%;PHC组血清GP73及AFP-L3含量明显高于肝硬化组及对照组(P<0.05)。与GP73及AFP-L3单项检测比较,二者联合检测可明显提高PHC诊断的灵敏度、阴性预测值以及总有效率(P<0.05),而特异度和阳性预测值无显著性差异(P>0.05)。结论 GP73及AFP-L3含量在PHC患者血清中明显增高,且二者联合检测可提高PHC诊断效率,可作为PHC诊断的血清标志物。     

血清磷脂酰肌醇蛋白聚糖3联合AFP—L3％诊断原发性肝癌价值

目的探讨血清磷脂酰肌醇蛋白聚糖3（Glypican3,GPC3）联合甲胎蛋白异质体（alpha{etoproteinvariants,AFP-L3）占甲胎蛋白（alphafetoprotein,AFP）的百分比（AFP—L3％）在原发性肝癌诊断中的价值。方法原发性肝癌患者43例为肝癌组,慢性肝炎患者43例为肝炎组,肝硬化患者43例为肝硬化组,体检健康者43例为对照组,分别采用ELISA法和亲和吸附法检测4组GPC3和AFP—L3水平,计算AFP—L3％,并比较分析。结果血清GPC3和AFP—L3％从高到低依次为肝癌组（（10．94士0．58）μg／L和（15．85±2．74）％）、肝硬化组（（5．56±0．49）μg／L和（10．72±2．65）％）、肝炎组（（2．73±0．46）μg／L和（9．57土2．59）％）、对照组（（1．15±0．42）μg／L和（9．08±2．55）％）,肝炎组与对照组AFP-L3％比较差异无统计学意义（P〉0．05）,其他各组间上述指标比较差异均有统计学意义（P〈0．05）;与组织病理结果进行对照,AFP—L3％联合GPC3诊断原发性肝癌的符合率（81．40％）明显高于二者单独检测（48．84％、25．58％）（P〈0．01）。结论血清GPC3与AFP-L3％联合检测可提高原发性肝癌早期诊断准确率。     

血清GPC3联合AFP对原发性肝癌的诊断价值探讨

原发性肝癌早期诊断是改善预后的关键。AFP联合肝脏超声筛查和随访是早期诊断的主要途径，但对慢性肝病基础上较为常见的良性病变与小肝癌的鉴别仍较困难。AFP≥200μg／L作为诊断肝癌临界值（cut-off值），敏感度仅为20％～45％ AFP异质体（AFP-13）检测等对肝癌有很好的特异度，但是敏感度也低H0。磷脂酰肌醇硫酸类肝素蛋白聚糖3（glypican-3，GPC3）是通过磷脂酰肌醇（GPI）锚定于细胞膜表面脂质的硫酸类肝素蛋白聚糖，参与调节胚胎生长发育。国外研究显示，GPC3在80％～90％肝癌组织中表达水平显著上调，[第一段]     

Glypican-3和AFP联合检测对原发性肝细胞癌的诊断意义

目的通过检测磷脂酰肌醇蛋白聚糖-3(Glypican-3,GPC3)和甲胎蛋白(AFP)在原发性肝细胞癌(HCC)患者中的表达情况,探讨其联合检测对于HCC的诊断意义。方法采用ELISA和免疫组化的方法检测了89例肝细胞癌患者和30例健康人群血清和组织中的GPC3和AFP蛋白的表达情况,并进一步分析了GPC3的表达与HCC患者临床病理特征的相关性。结果 GPC3和AFP联合检测对HCC的诊断敏感性和特异性分别为91.0%和93.3%,显著高于GPC3或AFP单独检测的敏感性和特异性(P<0.05);且对AFP阴性的HCC患者,GPC3表达的阳性率亦较高。GPC3蛋白的表达与HBsAg以及是否转移无关,而与Edmondson病例分级及肿瘤大小相关。结论联合检测GPC3和AFP可有效提高临床对于HCC的诊断水平。     

血清GP73检测在原发性肝癌诊断中的价值

目的探讨血清中高尔基体蛋白73(GP73)对原发性肝癌(PHC)诊断的临床意义。方法应用ELISA法和化学发光免疫分析法分别对85例肝细胞癌、57例慢性肝炎、48例肝硬化和30例健康对照者血清中GP73及AFP进行定量检测。结果 GP73和AFP检测在肝癌组对PHC诊断的敏感度分别78.83%和64.71%;两者联合检测敏感度可提高至92.94%。结论 GP73对PHC诊断具有较好的敏感度,GP73和AFP联合诊断更有利于提高PHC的临床诊断。     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

目的 评价分析GP73和GP73 mRNA在PHC中的诊断价值,探讨血清中GP73和AFP联合检测对PHC诊断和高危人群普查的意义,为PHC诊断和普查提供一种新方法 .方法 采用ELISA对73例PHC、13例肝硬化、32例肝炎和62名健康人的血清GP73、AFP水平进行检测,采用SYBR Green实时荧光定量PCR法检测各组外周血单个核细胞GP73 mRNA的相对表达量,以Ct值比较法计算GP73 mRNA相对表达水平,同时检测分析8份正常肝组织和8份肝癌组织的GP73 mRNA相对表达水平.结果 ELISA检测4组血清GF73、AFP结果 显示,总体比较经Kruskal-Wallis检验,4组间差异有统计学意义(H值分别为89.6、52.0,P均＜0.01),全血GP73 mRNA含量4组间差异无统计学意义(H=4.33,P＞0.05).组间多重比较Mann-Whitney检验结果显示,PHC组血清GP73的含量[166.7(162.7-231.8)μL]与肝硬化[57.3(46.6～113.6)μg/L]、肝炎[29.6(26.2～54.5)μg/L]及健康对照组[25.1(20.8～29.4)μg/L]比较,差异有统计学意义(U值分别为246、297、349,P均＜0.01),各组血清AFP的含量分别为380.9(258.5～ 503.2)μg/L、3.8(1.3～14.5)μg/L、5.1(2.4～7.8)μg/L、2.8(2.2～5.7)μg/L,差异亦有统计学意义(U值分别为246、419、790,P均＜0.01).肝癌组织GP73 mRNA表达量(12.64)显著高于正常肝组织(1.00).以ROC曲线确定诊断PHC的GP73临界值为123.2μg/L和AFP临界值为10.6 μg/L时,PHC组血清GP73、AFP单项检测的敏感度分别为65.8%和53.4%,特异度分别为95.3%和92.5%,两者联合检测的敏感度为79.5%,特异度为90.7%.结论 GP73蛋白对PHC诊断具有较好的敏感度和特异度;全血标本GP73 mRNA检测不能作为诊断PHC的肿瘤标志,肝组织标本GP73 mRNA检测可作为诊断PHC的肿瘤标志,但存在创伤性大、风险大、患者痛苦等缺点.血清GP73联合AFP检测可有效提高PHC诊断,可用于PHC高危人群的普查及筛选.     

高尔基体蛋白73与AFP在原发性肝细胞癌筛查中的应用对比研究

目的对比高尔基体蛋白73(GP73)与AFP作为原发性肝细胞癌(HCC)筛查血清标记物的效果。方法收集2012年中山市肿瘤研究所对中山市小榄镇35⁶4岁年龄段的居民实施HCC筛查血清标本并收集临床HCC初治患者血清标本,分为5组:正常人群组95例,低危人群组100例,高危人群组95例,筛查HCC组9例,临床HCC组52例。对5组患者检测AFP及GP73,对二者诊断的敏感度、特异度及准确度进行比较。结果 GP73曲线下面积(AUROC)0.759(95%CI:0.68364岁年龄段的居民实施HCC筛查血清标本并收集临床HCC初治患者血清标本,分为5组:正常人群组95例,低危人群组100例,高危人群组95例,筛查HCC组9例,临床HCC组52例。对5组患者检测AFP及GP73,对二者诊断的敏感度、特异度及准确度进行比较。结果 GP73曲线下面积(AUROC)0.759(95%CI:0.683⁰.836),敏感度为72.1%,特异度为63.1%,最佳临界点为98.60 ng/L。AFP的AUROC为0.857(95%CI:0.7920.836),敏感度为72.1%,特异度为63.1%,最佳临界点为98.60 ng/L。AFP的AUROC为0.857(95%CI:0.792⁰.992),敏感度为59.0%,特异度为76.0%,最佳临界点为20.40 ng/L。GP73联合AFP检测,灵敏度为86.9%,特异度为98.3%,AUROC为0.926(95%CI:0.8750.992),敏感度为59.0%,特异度为76.0%,最佳临界点为20.40 ng/L。GP73联合AFP检测,灵敏度为86.9%,特异度为98.3%,AUROC为0.926(95%CI:0.875⁰.976)。结论 GP73准确度低于AFP,灵敏度高于AFP,因此应用于HCC筛查有其独特优势;GP73和AFP联合检测可提高HCC筛查效果。     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

Objective To explore the diagnostic value of GP-/3 protein in gene detection in the patient of primary hepatic carcinoma, to discuss the joint roles of serum GP73 and AFP, and provide a novel method for the diagnosis for PHC and screening for high-risk population. Methods ELISA was used to detect the serum level of GP73 and AFP in 73 cases of PHC, 13 cases of hepatic cirrhosis, 32 cases of hepatitis and 62 cases of health people. SYBR Green real time fluorescence quantitative PCR was used to detect the relative value of GP73 mRNA in the peripheral blood cells of each group. Comparative Ct method was used to evaluate the relative expression levels. Eight cases of normal liver tissues and 8 cases of PHC tissues were detected at the same time to compare the relative expression levels. Results Kruskal-Wallis test showed that the serum levels of GP73 and AFP had significant differences between four groups(H value were 89. 6 and 52.0, P ＜ 0. 01) and the whole blood GP73 mRNA had no significant differences(H =4. 33, P ＞ 0. 05). Mann-Whitney test showed that the serum levels of GP73 had significant differences among PHC groups[166. 7 (162. 7-231.8) μg/L] and liver cirrhosis[57. 3 (46. 6-113. 6) μg/L], hepatitis[29. 6(26. 2-54. 5) μg/L], health group[25.1 (20. 8-29. 4) μg/L] (U value were 246, 297, 349, P ＜ 0. 01).The A FP levels of the four groups were 380. 9 (258.5-503.2) μg/L, 3.8 (1.3-14. 5) μg/L, 5. 1 (2. 4-7. 8)μg/L and 2. 8(2. 2-5.7) μg/L. It also showed significant differences (U value were 246,419 and 790,P ＜0. 01). The GP73 mRNA expression of PHC liver tissues(12. 64) was significant higher than normal liver tissues (1.00). The critical values for GP73 and AFP was determined to be 123. 2 μg/L and 10. 6 μg/L through the 8OC curves. Under the critical value the sensitivity of GP73 and AFP were 65.8% and 53.4% ,and the specificity of CP73 and AFP were 95.3% and 92. 5% respectively. Joint detection could increase the sensitivity up to 79. 5%, and achieve the high specificity of 90. 7%. Conclusions As a new diagnositic marker of primary hepatic carcinoma, GP73 protein has the very good sensitivity and specificity. The GP73 mRNA in the whole blood sample could not be used for the diagnosis of PHC. But it woule be a good molecular marker for diagnosis of PHC in the liver tissue sample. The joint detection of GP73 and AFP could improve PHC diagnostic performance, and provide an effective approcach to the PHC high-risk screening.     

高尔基体蛋白73及其基因检测对原发性肝癌诊断的价值

Objective To explore the diagnostic value of GP-/3 protein in gene detection in the patient of primary hepatic carcinoma, to discuss the joint roles of serum GP73 and AFP, and provide a novel method for the diagnosis for PHC and screening for high-risk population. Methods ELISA was used to detect the serum level of GP73 and AFP in 73 cases of PHC, 13 cases of hepatic cirrhosis, 32 cases of hepatitis and 62 cases of health people. SYBR Green real time fluorescence quantitative PCR was used to detect the relative value of GP73 mRNA in the peripheral blood cells of each group. Comparative Ct method was used to evaluate the relative expression levels. Eight cases of normal liver tissues and 8 cases of PHC tissues were detected at the same time to compare the relative expression levels. Results Kruskal-Wallis test showed that the serum levels of GP73 and AFP had significant differences between four groups(H value were 89. 6 and 52.0, P ＜ 0. 01) and the whole blood GP73 mRNA had no significant differences(H =4. 33, P ＞ 0. 05). Mann-Whitney test showed that the serum levels of GP73 had significant differences among PHC groups[166. 7 (162. 7-231.8) μg/L] and liver cirrhosis[57. 3 (46. 6-113. 6) μg/L], hepatitis[29. 6(26. 2-54. 5) μg/L], health group[25.1 (20. 8-29. 4) μg/L] (U value were 246, 297, 349, P ＜ 0. 01).The A FP levels of the four groups were 380. 9 (258.5-503.2) μg/L, 3.8 (1.3-14. 5) μg/L, 5. 1 (2. 4-7. 8)μg/L and 2. 8(2. 2-5.7) μg/L. It also showed significant differences (U value were 246,419 and 790,P ＜0. 01). The GP73 mRNA expression of PHC liver tissues(12. 64) was significant higher than normal liver tissues (1.00). The critical values for GP73 and AFP was determined to be 123. 2 μg/L and 10. 6 μg/L through the 8OC curves. Under the critical value the sensitivity of GP73 and AFP were 65.8% and 53.4% ,and the specificity of CP73 and AFP were 95.3% and 92. 5% respectively. Joint detection could increase the sensitivity up to 79. 5%, and achieve the high specificity of 90. 7%. Conclusions As a new diagnositic marker of primary hepatic carcinoma, GP73 protein has the very good sensitivity and specificity. The GP73 mRNA in the whole blood sample could not be used for the diagnosis of PHC. But it woule be a good molecular marker for diagnosis of PHC in the liver tissue sample. The joint detection of GP73 and AFP could improve PHC diagnostic performance, and provide an effective approcach to the PHC high-risk screening.     

血清高尔基体蛋白73和甲胎蛋白在肝细胞肝癌诊断中价值

目的探讨血清高尔基体蛋白73（Golgi protein 73,GP73）和甲胎蛋白（alpha—fetoprotein,AFP）对肝细胞肝癌（hepatocellular carcinoma,HCC）的诊断价值。方法150例HCC患者为HCC组,108例慢性肝炎患者为慢性肝炎组,100例体检健康者为对照组,采用双抗体夹心酶联免疫法检测3组血清GP73水平,采用电化学发光免疫分析法检测AFP水平。结果HCC组血清GP73（212．8（87．0,279．1）μg／L）、AFP（5212．8（1587,22279．1）μg／L）水平高于慢性肝炎组（55．3（27．0,83．2）μg／L和3．5（1．7,15．5）μg／L）和对照组（52．9（17．0,80．4）μg／L和2．9（1．5,14．7）μg／L）（P均〈0．05）;HCC组GP73、AFP阳性率分别为69％和70％,二者联合检测诊断HCC的敏感性为83％。结论血清GP73在HCC中高表达,可鉴别肝脏的良、恶性疾病,与AFP联合检测可提高检出率。     

原发性肝癌中高尔基体蛋白73表达与淋巴细胞亚群的相关性

目的:探讨原发性肝癌患者高尔基体蛋白73(GP73)的表达与外周血淋巴细胞亚群的相关性及其可能的临床意义.方法:收集2018年6月～2020年7月确诊为原发性肝癌患者129例及健康对照者36例,检测外周血血清GP73的表达量并根据临界值将原发性肝癌患者划分为阳性组和阴性组;流式细胞术检测外周血淋巴细胞亚群百分数.采用S...     

血清甲胎蛋白异质体、高尔基体糖蛋白-73及甲胎蛋白检测在老年人原发性肝癌的诊断价值

目的探讨血清甲胎蛋白异质体(AFP-L3)、高尔基体糖蛋白-73(GP73)及甲胎蛋白(AFP)检测在老年人原发性肝癌(HCC)的诊断价值。 方法研究对象为2014年1月至2016年3月就诊于福建医科大学附属第二医院普外科年龄>60岁的老年患者,共80例;其中HCC组40例,肝良性肿瘤组21例,肝硬化组19例。采用双抗体夹心酶联免疫吸附测定(ELISA)法检测血清GP73水平,电化学发光法检测血清AFP和AFP-L3水平,微量离心柱法分离AFP-L3,并计算甲胎蛋白异质体比例(AFP-L3%)。绘制受试者工作特征曲线(ROC),分析AFP、AFP-L3、AFP-L3%、GP73单独用于HCC鉴别诊断效果。所有入组患者均签署知情同意书,经医院伦理委员会研究通过。 结果各组间血清AFP、AFP-L3、AFP-L3%、GP73水平差异有统计学意义(F＝213.04,151.98,231.80,657.04;P<0.01)。HCC组血清AFP、AFP-L3、AFP-L3%、GP73水平[(681.41±195.56)μg/L,(138.11±44.00)μg/L,(15.31±3.28)%,(158.18±14.78)μg/L]高于肝良性肿瘤组[(7.94±3.50)μg/L,(0.41±0.28)μg/L,(3.58±0.51)%,(49.26±8.76)μg/L],差异具有统计学意义(q＝22.41,22.21,25.18,47.34;P<0.01);HCC组高于肝硬化组[(64.19±33.59)μg/L,(3.94±2.91)μg/L,(4.23±0.71)%,(46.88±11.64)μg/L],差异具有统计学意义(q＝25.18,23.56,27.72,47.63;P<0.01)。ROC曲线下面积分别为0.744,0.799,0.720,0.875;GP73曲线下面积最大。AFP诊断HCC敏感度及特异度为62.5%、80.0%,AFP-L3诊断HCC敏感度及特异度为70.0%、77.5%,GP73诊断HCC敏感度及特异度为90.0%、70.0%。AFP与AFP-L3联合检测后敏感度为86.7%,特异度为95.5%;AFP与GP73联合检测后敏感度为96.3%,特异度为95.5%;AFP-L3与GP73联合检测后敏感度为97.0%,特异度为93.3%。 结论GP73、AFP-L3有望成为新的诊断原发性肝癌的血清标志物,血清AFP-L3、GP73、AFP联合检测联合应用能弥补单项血清标志物的不足,对提高老年HCC的诊断具有一定价值。     

血清甲胎蛋白、a-L-岩藻糖苷酶、a1-抗胰蛋白酶在原发性肝癌诊断中的应用

目的探讨甲胎蛋白(alpha fetoprotein,AFP)、a-L-岩藻糖苷酶(a-L-fucosidase,AFU)、a1-抗胰蛋白酶(alphao-antitrypsin,AAT)在原发性肝癌(PHC)患者诊断中的应用价值。方法选择126例原发性肝癌患者、397例良性肝病患者以及206名健康对照者,应用化学发光法测定AFP,新型CNPF(2-氯-4-硝基苯-a-L-岩藻吡喃糖苷)连续监测法测定AFU,速率散射比浊法测定AAT。结果原发性肝癌组AFP、AFU、APT与良性肝病组及健康对照组差异有显著性(P<0.01),单独检测对PHC诊断的阳性率分别为73.8%、85.7%、84.1%,三者联合检测可将PHC诊断阳性率提高到96%。结论血清AFU、AAT、与AFP互为补充,联合检测可提高对PHC的诊断率。